Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3
Open Access
- 15 December 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 112 (13), 5095-5102
- https://doi.org/10.1182/blood-2007-12-129718
Abstract
Constitutive activation of the transcription factor STAT3 contributes to the pathogenesis of many cancers, including multiple myeloma (MM). Since STAKeywords
This publication has 35 references indexed in Scilit:
- CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell CarcinomaClinical Cancer Research, 2007
- STAT3 as a central mediator of neoplastic cellular transformationCancer Letters, 2006
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Identification of Human STAT5-dependent Gene Regulatory Elements Based on Interspecies HomologyPublished by Elsevier ,2006
- STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomasOncogene, 2006
- Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancerNature Clinical Practice Oncology, 2005
- Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cellsBlood, 2004
- Isolation of Unique STAT5 Targets by Chromatin Immunoprecipitation-based Gene IdentificationPublished by Elsevier ,2004
- The Jak-STAT pathwayMolecular Immunology, 2000
- Requirement of Serine Phosphorylation for Formation of STAT-Promoter ComplexesScience, 1995